Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2023;34(4):577-80
Article Links
Clinical, Serological, and Immunological Characteristics of Greek Patients with Polymyalgia Rheumatica and/or Giant Cell Arteritis: A Research Protocol
Tereza Memi, Nikolaos Koletsos, Nafsika Gerolymatou, Maria Karakosta, Athanasios N. Georgiadis, Alexandros A. Drosos, Paraskevi V. Voulgari
Authors Information

Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

Keywords: polymyalgia rheumatica, giant cell arteritis, biomarkers, pentraxin, osteopontin, calprotectin
References
  1. Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol 2017;13(10):578–92.
  2. Weyand CM, Goronzy JJ. Giant-Cell Arteritis and Polymyalgia Rheumatica. Solomon CG, editor. N Engl J Med 2014;371(1):50.
  3. González-Gay MA, Matteson EL, Castañeda S. Polymyalgia rheumatica. Lancet 2017;390(10103):1700–12.
  4. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61(10):1454–61.
  5. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58(1):26–35.
  6. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA 2016;315(22):2442–58.
  7. Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology 2017;56(4):506–15.
  8. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011;63(3):633–9.
  9. Andel PM, Chrysidis S, Geiger J, Haaversen ACB, Haugeberg G, Myklebust G, et al. Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist. Rheumatology (Oxford) 2021;60(11):4958–71.
  10. Papadopoulos CG, Voulgari P V., Zioga A, Miltiadous GA, Nicolopoulos P, Elisaf MS, et al. Significant improvement of axillary artery stenosis in a 67 year-old woman with giant cell arteritis. Clin Exp Rheumatol 2008;26(3 Suppl 49):151–2.
  11. Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012;71(4):484–92.
  12. Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis. Arthritis Rheumatol 2022;0(0):1–9.
  13. González-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WER. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003;33(1):38–48.
  14. Carmona FD, González-Gay MA, Martín J. Genetic component of giant cell arteritis. Rheumatology (Oxford) 2014;53(1):6–18.
  15. Smutny T, Barvik I, Veleta T, Pavek P, Soukup T. Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis. J Clin Med 2019;8(5).
  16. Prieto-Peña D, Castañeda S, Atienza-Mateo B, Blanco R, González-Gay MA. Predicting the risk of relapse in polymyalgia rheumatica: novel insights. Expert Rev Clin Immunol 2021;17(3):225–32.
  17. Carvajal Alegria G, Boukhlal S, Cornec D, Devauchelle-Pensec V. The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. Autoimmun Rev 2020;19(11).
  18. Weyand CM, Goronzy JJ. Immune Mechanisms in Medium and Large Vessel Vasculitis. Nat Rev Rheumatol 2013;9(12):731.
  19. Rubenstein E, Maldini C, Gonzalez-Chiappe S, Chevret S, Mahr A. Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis. Rheumatology (Oxford) 2020;59(5):1011–20.
  20. Kaltsonoudis E, Pelechas E, Papoudou-Bai A, Markatseli TE, Elisaf M, Voulgari PV, et al. The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital. PLoS One 2019;14(3).
  21. Baldini M, Maugeri N, Ramirez GA, Giacomassi C, Castiglioni A, Prieto-González S, et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum 2012;64(3):854–65.
  22. Pulsatelli L, Peri G, Macchioni P, Boiardi L, Salvarani C, Cantini F, et al. Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica. Clin Exp Rheumatol 2010;28(5):756–8.
  23. Ramirez GA, Rovere-Querini P, Blasi M, Sartorelli S, Di Chio MC, Baldini M, et al. PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases. Front Immunol 2019;10.
  24. Prieto-González S, Terrades-García N, Corbera-Bellalta M, Planas-Rigol E, Miyabe C, Alba MA, et al. Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. RMD Open 2017;3(2).
  25. Van Sleen Y, Sandovici M, Abdulahad WH, Bijzet J, Van Der Geest KSM, Boots AMH, et al. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology (Oxford) 2019;58(8):1383–92.
  26. Austermann J, Spiekermann C, Roth J. S100 proteins in rheumatic diseases. Nat Rev Rheumatol 2018;14(9):528–41.
  27. Stríz I, Trebichavský I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol Res 2004;53(3):245–53.
  28. Springer JM, Monach P, Cuthbertson D, Carette S, Khalidi NA, McAlear CA, et al. Serum S100 Proteins as a Marker of Disease Activity in Large Vessel Vasculitis. J Clin Rheumatol 2018;24(7):393–5.
  29. World Medical Association Declaration of Helsinki. JAMA 2013;310(20):2191.